iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024 08:26 ET
|
iTeos Therapeutics Inc.
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...
iTeos Therapeutics Announces $120 Million Registered Direct Offering
May 10, 2024 08:24 ET
|
iTeos Therapeutics Inc.
- Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma...
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
May 10, 2024 08:24 ET
|
Clearmind Medicine Inc.
The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0)...
Aqua Metals Joins $4.99 Million DOE Grant Project to Pioneer Domestic Critical Mineral Supply Chain
May 10, 2024 08:10 ET
|
Aqua Metals
RENO, Nev., May 10, 2024 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling technology, is proud to announce its collaboration in a...
Telos Corporation Announces First Quarter Results Above Guidance: Reports $29.6 Million of Revenue, 37.0% GAAP Gross Margin, and 42.2% Cash Gross Margin
May 10, 2024 08:02 ET
|
Telos Corporation
Reports First Quarter Results Above High End of Guidance Range on Key Financial MetricsDelivered $29.6 Million of Revenue, Reflecting Outperformance by Security SolutionsGenerated 37.0% GAAP Gross...
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
May 10, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies...
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024 08:00 ET
|
Prime Medicine, Inc.
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- --...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
May 10, 2024 08:00 ET
|
Eterna Therapeutics
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Mobile-health Network Solutions Expands Services to Malaysia
May 10, 2024 08:00 ET
|
Mobile-heath Network Solutions
SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced the establishment...
Ekso Indego Personal to be Featured on ‘Health Uncensored’ with Dr. Drew Pinsky
May 10, 2024 08:00 ET
|
Ekso Bionics Holdings, Inc.
Segment to appear on Fox Business News on Sunday, May 12 at 5:30 p.m. ET SAN RAFAEL, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso...